Zacks Small Cap Research on MSN
CVKD acquires 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT)
By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc.
April 24, 2008 (Cambridge, MA) – More details of the contaminant found in heparin--oversulfated chondroitin sulfate (OSCS)--and the mechanism by which it is believed to bring about adverse events have ...
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results